GVAX Plus Checkpoint Blockade in Neuroblastoma

Conditions:   Neuroblastoma;   Pediatric Solid Tumor Interventions:   Procedure: Tissue collection;   Biological: GVAX vaccine;   Drug: Nivolumab;   Drug: Ipilimumab Sponsor:   Dana-Farber Cancer Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conditions:   Neuroblastoma;   Pediatric Solid Tumor Interventions:   Procedure: Tissue collection;   Biological: GVAX vaccine;   Drug: Nivolumab;   Drug: Ipilimumab Sponsor:   Dana-Farber Cancer Institute Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, the recombinant nonstructural 2B protein of EV-A71 was successfully produced in human neuroblastoma SH-SY5Y cells and evaluated for its effects on induction of the cell apoptosis and the pathway involved. The EV-A71 2B-transfected SH-SY5Y cells showed significantly higher difference in the cell growth inhibition than the mock and the irrelevant protein controls. The transfected SH-SY5Y cells underwent apoptosis and showed the significant upregulation of caspase-9 (CASP9) and caspase-12 (CASP12) genes at 3- and 24-h post-transfection, respectively. Interestingly, the level of cytosolic Ca2+ was significantly ...
Source: Journal of NeuroVirology - Category: Neurology Source Type: research
ConclusionsThese data suggest that a combined innate and adaptive immunotherapeutic approach can be effective against immunologically cold syngeneic murine neuroblastoma. Further testing is needed to determine how these concepts might translate into development of more effective immunotherapeutic approaches for the treatment of clinically high-risk neuroblastoma.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
This study demonstrates for the first time that senescent cells secrete functional LTs, significantly contributing to the LTs pool known to cause or exacerbate idiopathic pulmonary fibrosis. Against Senolytics https://www.fightaging.org/archives/2019/11/against-senolytics/ There is no consensus in science that is so strong as to have no heretics. So here we have an interview with a naysayer on the matter of senolytic treatments, who argues that the loss of senescent cells in aged tissues will cause more harm to long-term health than the damage they will do by remaining. To be clear, I think this to be a ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Despite efforts to develop novel treatment strategies, refractory and relapsing sarcoma, and high-risk neuroblastoma continue to have poor prognoses and limited overall survival. Monocyte-derived dendritic cell (DC)-based anti-cancer immunotherapy represents a promising treatment modality in these neoplasias. A DC-based anti-cancer vaccine was evaluated for safety in an academic phase-I/II clinical trial for children, adolescents, and young adults with progressive, recurrent, or primarily metastatic high-risk tumors, mainly sarcomas and neuroblastomas. The DC vaccine was loaded with self-tumor antigens obtained from patien...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Relapsed Neuroblastoma Interventions:   Biological: DNA vaccine;   Biological: Salmonella oral vaccine;   Drug: Lenalidomide Sponsor:   Belarusian Research Center for Pediatric Oncology, Hematology and Immunology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brain | Cancer & Oncology | Neuroblastoma | Neurology | Pediatrics | Research | Vaccines | Yervoy